15 articles for MD Hill
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
BMS-933043, a Selectivea7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
Bristol-Myers Squibb
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.
Bristol-Myers Squibb
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] asa7 Nicotinic Receptor Agonists.
Bristol-Myers Squibb Research and Development
Applications of Fluorine in Medicinal Chemistry.
Bristol-Myers Squibb Research and Development
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.
Bristol Myers Squibb
Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype.
Bristol Myers Squibb Research and Development
Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.
Bristol Myers Squibb Research and Development
Design and synthesis of a novel series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor.
Bristol-Myers Squibb Pharmaceutical Research Institute
Development of spiroguanidine-derivedα7 neuronal nicotinic receptor partial agonists.
Bristol-Myers Squibb Research and Development
Benzenesulfonamide compounds and their use as therapeutic agents
Xenon Pharmaceuticals
Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Beigene